Label: BACITRACIN ointment

  • NDC Code(s): 0574-4022-01, 0574-4022-11, 0574-4022-13, 0574-4022-35
  • Packager: Padagis US LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 16, 2022

If you are a consumer or patient please visit this version.

  • STERILE Rx Only

  • DESCRIPTION:

    Each gram of ointment contains 500 units of Bacitracin in a low melting special base containing White Petrolatum and Mineral Oil.

  • CLINICAL PHARMACOLOGY:

    The antibiotic, Bacitracin, exerts a profound action against many gram-positive pathogens, including the common Streptococci and Staphlococci. It is also destructive for certain gram-negative organisms. It is ineffective against fungi.

  • INDICATIONS AND USAGE:

    For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

  • CONTRAINDICATIONS:

    This product should not be used in patients with a history of hypersensitivity to Bacitracin.

  • PRECAUTIONS:

    Bacitracin ophthalmic ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic. The prolonged use of antibiotic containing preparations may result in overgrowth of nonsusceptible organisms particularly fungi. If new infections develop during treatment appropriate antibiotic or chemotherapy should be instituted.

  • ADVERSE REACTIONS:

    Bacitracin has such a low incidence of allergenicity that for all practical purposes side reactions are practically non-existent. However, if such reaction should occur, therapy should be discontinued.

    To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • DOSAGE AND ADMINISTRATION:

    The ointment should be applied directly into the conjunctival sac 1 to 3 times daily. In blepharitis all scales and crusts should be carefully removed and the ointment then spread uniformly over the lid margins. Patients should be instructed to take appropriate measures to avoid gross contamination of the ointment when applying the ointment directly to the infected eye.

  • HOW SUPPLIED:

    NDC 0574-4022-35 3.5 g (1/8 oz.) sterile tamper evident tubes with ophthalmic tip.

    Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

  • SPL UNCLASSIFIED SECTION

    Made in Canada

    Manufactured by Jubilant HollisterStier General Partnership
    Kirkland, Quebec H9H 4J4 Canada

    Distributed By Perrigo, Allegan, MI 49010

    Minneapolis, MN 55427

    35F00 RC J1

    Rev 08-21

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 3.5 g Carton

    Rx Only

    NDC 0574-4022-35

    Bacitracin Ophthalmic Ointment USP

    NET WT 3.5 g (1/8 oz)

    STERILE

    carton

    The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

    serialization-template
  • INGREDIENTS AND APPEARANCE
    BACITRACIN 
    bacitracin ointment
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0574-4022
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BACITRACIN (UNII: 58H6RWO52I) (BACITRACIN - UNII:58H6RWO52I) BACITRACIN500 [USP'U]  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    PETROLATUM (UNII: 4T6H12BN9U)  
    MINERAL OIL (UNII: T5L8T28FGP)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0574-4022-011 in 1 CARTON03/10/201409/01/2016
    1NDC:0574-4022-111 g in 1 TUBE; Type 0: Not a Combination Product
    2NDC:0574-4022-133 in 1 CARTON03/10/201409/01/2016
    2NDC:0574-4022-111 g in 1 TUBE; Type 0: Not a Combination Product
    3NDC:0574-4022-351 in 1 CARTON03/10/2014
    33.5 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06121203/10/2014
    Labeler - Padagis US LLC (967694121)